[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100574730":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":12,"locations":18,"responsibleParty":49,"collaborators":52,"id":59,"slug":7,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":60,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":7,"studyType":72,"phases":7,"briefSummary":73,"conditions":74,"keywords":81,"overallStatus":21,"whyStopped":7,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"University of Manitoba","OTHER",null,[9],{"type":6,"name":10,"description":11,"armGroupLabels":7,"otherNames":7},"Not applicable- observational study","It's an observational study. Participants are not assigned an intervention as part of the study.",[13],{"name":14,"role":15,"phone":16,"phoneExt":7,"email":17},"Abdullah A Maruf, BPharm, MPharm, PhD","CONTACT","204-318-2575","abdullah.maruf@umanitoba.ca",[19,35],{"facility":20,"status":21,"city":22,"state":23,"zip":24,"country":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":32},"Shared Health Facilities","RECRUITING","Winnipeg","Manitoba","R3C 3H8","Canada",{"type":27,"coordinates":28},"Point",[29,30],-97.14704,49.8844,{"lat":30,"lon":29},[33],{"name":34,"role":15,"phone":16,"phoneExt":7,"email":17},"Abdullah Al Maruf, PhD, M.Pharm., B.Pharm",{"facility":36,"status":21,"city":22,"state":23,"zip":37,"country":25,"cosmosGeoPoint":38,"geoPoint":40,"contacts":41},"University of Manitoba College of Pharmacy","R3E 0T5",{"type":27,"coordinates":39},[29,30],{"lat":30,"lon":29},[42,44,47],{"name":43,"role":15,"phone":16,"phoneExt":7,"email":17},"Abdullah Al Maruf, PhD, M.Pharm, B.Pharm",{"name":45,"role":15,"phone":7,"phoneExt":7,"email":46},"Mahin Hasan, MSc, BSc","hasanm33@myumanitoba.ca",{"name":43,"role":48,"phone":7,"phoneExt":7,"email":7},"PRINCIPAL_INVESTIGATOR",{"type":48,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Abdullah Al Maruf","Assistant Professor",[53,55,57],{"name":54,"class":6},"Health Sciences Centre Foundation, Manitoba",{"name":56,"class":6},"Children's Hospital Research Institute of Manitoba",{"name":58,"class":6},"University of Calgary","100574730",false,"NCT06763081","Pharmacogenomics of Selective Serotonin Reuptake Inhibitor (SSRI)-Induced Behavioural Activation","Pharmacogenomics of Selective Serotonin Reuptake Inhibitor (SSRI)-Induced Behavioural Activation in Children and Youth (PGx-SImBA)","PGx-SImBA","Inclusion criteria: Participants will be eligible for participation if all of the following are true.\n\n* Resident of Manitoba\n* Age, 6 - 24 years\n* Diagnosis of major depressive disorder (MDD), anxiety disorder, or obsessive-compulsive disorder (OCD)\n* Current or past history of selective serotonin reuptake inhibitor (SSRI), e.g., Citalopram \\[Celexa\\], Escitalopram \\[Cipralex\\], Fluoxetine \\[Prozac\\], Fluvoxamine \\[Luvox\\], Sertraline \\[Zoloft\\], Paroxetine \\[Paxil\u002FPlaxil CR\\]) therapy\n* \\[Cases Only\\] Have experienced behavioural side effects after taking an SSRI that resolved after reducing the dose or discontinuation of the drug\n* \\[Controls Only\\] Did not experience any side effects after taking an SSRI for eight (8) continuous weeks\n\nExclusion criteria: Participants will be excluded from participation if any of the following are true.\n\n* Inability of parent\u002Flegal guardian\u002Fmature minors to give informed consent\n* Inability of the child (6 - 13 years) to give informed assent\n* Unwillingness of the child to provide a saliva sample for genetic analysis\n* Current, past, or suspected diagnosis of attention deficit hyperactivity disorder (combined or hyperactive type), oppositional defiant disorder, conduct disorder, bipolar disorder, psychotic disorder, pervasive developmental disorder\n* History of liver or bone marrow (hematopoietic cell) transplant.","ALL","6 Years","24 Years",{"count":70,"type":71},160,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to identify and validate a panel of genetic markers associated with selective serotonin reuptake inhibitors (SSRI)-induced behavioural activation in children and youth with major depressive disorder (MDD), anxiety disorders, or obsessive-compulsive disorder (OCD) that could be used clinically to reduce the incidence of this adverse event and improve health outcomes.",[75,76,77,78,79,80],"Behavioral Activation","Major Depressive Disorder","Anxiety Disorders","Antidepressant Drug Adverse Reaction","Obsessive Compulsive Disorder (OCD)","Major Depression",[82,83,84,85,86,87,88,89,90,91,92,93,94,95,96],"SSRI","Depression","OCD","Anxiety","Antidepressants","Children","Adolescents","Mood Disorders","Drug-induced Adverse Events","Youth","Mental Illness","Mental disorders","Drug-Related Side Effects and Adverse Reactions","Selective Serotonin Reuptake Inhibitor","Disinhibition","2025-09-01",{"date":99,"type":100},"2025-09-08","ACTUAL",{"date":102,"type":100},"2025-03-01",{"date":104,"type":71},"2030-12-31",{"name":5,"class":6},2]